Establishment of the H8T-MG Meningioma Cell Line and Integrated Transcriptomics Reveal a Metabolic–Immune Signature in Diploid Transitional WHO Grade 1 Tumours
Abstract
1. Introduction
2. Materials and Methods
- Establishment of the H8T-MG meningioma cell line derived from a diploid transitional WHO grade 1 tumour (DT-G1); immunocytochemical and cytogenetic characterization
- Establishment of the H16T-MG long-term primary meningioma culture; immunocytochemical characterization
- Bioinformatics analysis
3. Results
3.1. Establishment and Morphological Characterization of the H8T-MG Meningioma Cell Line
3.1.1. Establishment of the Grade 1 Meningioma Cell Line H8T-MG
3.1.2. Morphology of H8T-MG Cultures
3.1.3. Growth Kinetics
3.1.4. Immunocytochemical Characterization of H8T-MG
3.1.5. Karyotyping of H8T-MG
3.2. Characterization of the H16T-MG Long-Term Primary Culture
3.3. Bioinformatics Analysis of Transcriptomic Differences Between Normal Meninges and DT-G1 Meningiomas
3.3.1. Exploratory Analysis of Raw Microarray Data
3.3.2. Normalization and Quality Assessment of Processed Microarray Data
3.3.3. Differential Expression Overview
3.3.4. Differential Expression Patterns Visualized by Volcano Plot
3.3.5. Hierarchical Clustering of Differentially Expressed Genes
3.3.6. Gene Ontology Enrichment Analysis
3.3.7. KEGG Pathway Enrichment Analysis
- IL-17 signalling pathway;
- TNF signalling pathway;
- Cytoskeleton in muscle cells;
- Arachidonic acid metabolism;
- Lipid and atherosclerosis;
- Drug metabolism—cytochrome P450;
- Chemical carcinogenesis—DNA adducts;
- Retinol metabolism;
- Malaria (shared inflammatory–vascular component);
- African trypanosomiasis (shared inflammatory–vascular component).
| Category | Subcategory | Description | p-Value | p-Adjust | Count | GeneID (NCBI) | Gene Symbol | Direction of Gene Deregulation Benign Transitional Diploid Meningioma vs. Meninges |
|---|---|---|---|---|---|---|---|---|
| Human Diseases (hsa05144) | Infectious disease: parasitic | Malaria | 1.347 × 10−6 | 0.0001953688 | 5 | 6347/3043/6401/7057/3569 | CCL2 | ↓ in Meningiomas Grade 1 |
| HBB | ↓ in Meningiomas Grade 1 | |||||||
| SELE | ↓ in Meningiomas Grade 1 | |||||||
| THBS1 | ↓ in Meningiomas Grade 1 | |||||||
| IL6 | ↓ in Meningiomas Grade 1 | |||||||
| Organismal Systems (hsa04657) | Immune system | IL-17 signaling pathway | 3.243 × 101 | 0.0023512379 | 4 | 6347/5743/3569/6279 | CCL2 | ↓ in Meningiomas Grade 1 |
| PTGS2 | ↓ in Meningiomas Grade 1 | |||||||
| IL6 | ↓ in Meningiomas Grade 1 | |||||||
| S100A8 | ↓ in Meningiomas Grade 1 | |||||||
| Metabolism (hsa00590) | Lipid metabolism | Arachidonic acid metabolism | 9.156 × 101 | 0.0034617933 | 4 | 1555/1557/1558/5743 | CYP2B6 | ↑ in Meningiomas Grade 1 |
| CYP2C19 | ↓ in Meningiomas Grade 1 | |||||||
| CYP2C9 | ↓ in Meningiomas Grade 1 | |||||||
| PTGS2 | ↓ in Meningiomas Grade 1 | |||||||
| Environmental Information Processing (hsa04668) | Signal transduction | TNF signaling pathway | 9.550 × 101 | 0.0034617933 | 4 | 6347/5743/6401/3569 | CCL2 | ↓ in Meningiomas Grade 1 |
| PTGS2 | ↓ in Meningiomas Grade 1 | |||||||
| SELE | ↓ in Meningiomas Grade 1 | |||||||
| IL6 | ↓ in Meningiomas Grade 1 | |||||||
| Human Diseases (hsa05204) | Cancer: overview | Chemical carcinogenesis - DNA adducts | 1.658 × 102 | 0.0038248597 | 4 | 1548/1557/1558/5743 | CYP2A6 | ↑ in Meningiomas Grade 1 |
| CYP2C19 | ↓ in Meningiomas Grade 1 | |||||||
| CYP2C9 | ↓ in Meningiomas Grade 1 | |||||||
| PTGS2 | ↓ in Meningiomas Grade 1 | |||||||
| Human Diseases (hsa05417) | Cardiovascular disease | Lipid and atherosclerosis | 1.781 × 102 | 0.0038248597 | 6 | 1555/1548/1558/6347/6401/3569 | CYP2B6 | ↑ in Meningiomas Grade 1 |
| CYP2A6 | ↑ in Meningiomas Grade 1 | |||||||
| CYP2C9 | ↓ in Meningiomas Grade 1 | |||||||
| CCL2 | ↓ in Meningiomas Grade 1 | |||||||
| SELE | ↓ in Meningiomas Grade 1 | |||||||
| IL6 | ↓ in Meningiomas Grade 1 | |||||||
| Metabolism (hsa00982) | Xenobiotics biodegradation and metabolism | Drug metabolism-cytochrome P450 | 1.846 × 102 | 0.0038248597 | 4 | 1555/1548/1557/1558 | CYP2B6 | ↑ in Meningiomas Grade 1 |
| CYP2A6 | ↑ in Meningiomas Grade 1 | |||||||
| CYP2C19 | ↓ in Meningiomas Grade 1 | |||||||
| CYP2C9 | ↓ in Meningiomas Grade 1 | |||||||
| Human Diseases (hsa05143) | Infectious disease: parasitic | African trypanosomiasis | 4.029 × 102 | 0.0073022271 | 3 | 3043/6401/3569 | HBB | ↓ in Meningiomas Grade 1 |
| SELE | ↓ in Meningiomas Grade 1 | |||||||
| IL6 | ↓ in Meningiomas Grade 1 | |||||||
| NA (hsa04820) | NA | Cytoskeleton in muscle cells | 2.035 × 103 | 0.0327837258 | 5 | 7134/7057/478/4629/1634 | TNNC1 | ↑ in Meningiomas Grade 1 |
| THBS1 | ↓ in Meningiomas Grade 1 | |||||||
| ATP1A2 | ↓ in Meningiomas Grade 1 | |||||||
| MYH11 | ↓ in Meningiomas Grade 1 | |||||||
| DCN | ↓ in Meningiomas Grade 1 | |||||||
| Metabolism (hsa00830) | Metabolism of cofactors and vitamins | Retinol metabolism | 2.389 × 103 | 0.0346464396 | 3 | 1555/1548/1558 | CYP2B6 | ↑ in Meningiomas Grade 1 |
| CYP2A6 | ↑ in Meningiomas Grade 1 | |||||||
| CYP2C9 | ↓ in Meningiomas Grade 1 |

3.3.8. PPI Network and Hub Gene Identification
| Gene Symbol | Description | Degree | Regulation | Main Function |
|---|---|---|---|---|
| ASPN | Asporin | 30 | ↓ | Extracellular matrix organisation; collagen binding |
| SELE | E-selectin | 26 | ↓ | Endothelial adhesion; inflammatory cell recruitment |
| ABCB1 (=MDR1) | ATP-binding cassette sub-family B member 1 (P-glycoprotein 1) | 24 | ↑ | ATP-dependent efflux transporter; xenobiotic/drug export |
| ACKR1 (=DARC) | Atypical chemokine receptor 1 (Duffy antigen receptor for chemokines | 22 | ↓ | Chemokine scavenging; immune-vascular modulation |
4. Discussion
4.1. Immunocytochemical Characterization of H8T-MG and H16T-MG
4.2. Transcriptomic Analysis
4.2.1. GO Enrichment Analysis
4.2.2. KEGG Pathway Enrichment Analysis
4.2.3. Hub Genes and PPI Network Interpretation
4.3. Integrative Summary
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ostrom, Q.T.; Patil, N.; Cioffi, G.; Waite, K.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020, 22, iv1–iv96. [Google Scholar]
- Mawrin, C.; Perry, A. Pathological classification and molecular genetics of meningiomas. J. Neuro Oncol. 2010, 99, 379–391. [Google Scholar] [CrossRef]
- Kalamarides, M.; Acosta, M.T.; Babovic-Vuksanovic, D.; Carpen, O.; Cichowski, K.; Evans, D.G.; Giancotti, F.; Hanemann, C.O.; Ingram, D.; Lloyd, A.C.; et al. Neurofibromatosis 2011: A report of the Children’s Tumor Foundation annual meeting. Acta Neuropathol. 2012, 123, 369–380. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Ostrom, Q.T.; Price, M.; Neff, C.; Cioffi, G.; Waite, K.A.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2016–2020. Neuro Oncol. 2023, 25, iv1–iv99. [Google Scholar] [CrossRef]
- Ruttledge, M.H.; Sarrazin, J.; Rangaratnam, S.; Piras, G.; Draheim, J.E.; Park, J.F.; Pulst, S.M.; Thornton, J.; Latif, F.; Lerman, M.I.; et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat. Genet. 1994, 6, 180–184. [Google Scholar] [CrossRef]
- Lekanne Deprez, R.H.; Riegman, P.H.; Groen, N.A.; Warringa, U.L.; van Biezen, N.A.; Molijn, A.C.; van Drunen, E.; Boots-Schoemaker, H.; Koper, J.W.; Avezaat, C.J.; et al. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J. Neuropathol. Exp. Neurol. 1995, 54, 224–235. [Google Scholar] [CrossRef] [PubMed]
- Korshunov, A.; Cherekaev, V.; Bekyashev, A.; Sycheva, R. Recurrent cytogenetic aberrations in histologically benign, invasive meningiomas of the sphenoid region. J. Neurooncol. 2007, 81, 131–137. [Google Scholar] [CrossRef] [PubMed]
- Weber, R.G.; Boström, J.; Wolter, M.; Baudis, M.; Collins, V.P.; Reifenberger, G. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Association with tumor progression and recurrence. Am. J. Pathol. 1997, 151, 799–806. [Google Scholar]
- Pfisterer, W.K.; Coons, S.W.; Aboul-Enein, F.; Laws, E.R., Jr.; Schwechheimer, K.; von Deimling, A. Cytogenetic progression in meningiomas: Evidence for chromosomal instability in aggressive tumors. J. Neuropathol. Exp. Neurol. 1999, 58, 675–682. [Google Scholar] [CrossRef]
- Tabernero, M.D.; Maillo, A.; Gil-Bellosta, C.J.; Castrillo, A.; Sousa, P.; Merino, M.; Orfao, A. Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol. 2009, 19, 409–420. [Google Scholar] [CrossRef]
- Soni, N.; Ora, M.; Bathla, G.; Szekeres, D.; Desai, A.; Pillai, J.J.; Agarwal, A. Meningioma: Molecular updates from the 2021 World Health Organization classification of CNS tumors and imaging correlates. AJNR Am. J. Neuroradiol. 2025, 46, 240–250. [Google Scholar] [CrossRef]
- Puduvalli, V.K.; Li, J.T.; Chen, L.; McCutcheon, I.E. Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res. 2005, 65, 1547–1553. [Google Scholar] [CrossRef]
- Püttmann, S.; Senner, V.; Braune, S.; Hillmann, B.; Exeler, R.; Rickert, C.H.; Paulus, W. Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab. Investig. 2005, 85, 1163–1171. [Google Scholar] [CrossRef]
- Baia, G.S.; Slocum, A.L.; Hyer, J.D.; Misra, A.; Sehati, N.; VandenBerg, S.R.; Feuerstein, B.G.; Deen, D.F.; McDermott, M.W.; Lal, A. A genetic strategy to overcome the senescence of primary meningioma cell cultures. J. Neurooncol. 2006, 78, 113–121. [Google Scholar] [CrossRef] [PubMed]
- Michelhaugh, S.K.; Guastella, A.R.; Varadarajan, K.; Klinger, N.V.; Genter, M.B.; Mittal, S. Development of patient-derived xenografts from meningioma specimens. J. Transl. Med. 2015, 13, 313. [Google Scholar] [CrossRef] [PubMed]
- Ishikawa, T.; Matsuda, M.; Ishikawa, H.; Toyomura, J.; Ohyama, A.; Sakamoto, N.; Zaboronok, A.; Ishikawa, E. Establishment of a novel benign meningioma cell line spontaneously immortalized under hypoxic conditions. Hum. Cell. 2024, 38, 22. [Google Scholar] [CrossRef] [PubMed]
- Miserocchi, G.; Mercatali, L.; Liverani, C.; De Vita, A.; Spadazzi, C.; Pieri, F.; Bongiovanni, A.; Recine, F.; Amadori, D.; Ibrahim, T. Management and potentialities of primary cancer cultures in preclinical and translational studies. J. Transl. Med. 2017, 15, 229. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Tang, H. Meningioma cell culture: Establishment, characterization and applications. J. Neurooncol. 2012, 107, 281–292. [Google Scholar]
- Sun, Y.; Wu, P.; Zhang, Z.; Wang, Z.; Zhou, K.; Song, M.; Ji, Y.; Zang, F.; Lou, L.; Rao, K.; et al. Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer Cell 2024, 42, 135–156.e17. [Google Scholar] [CrossRef]
- Dai, C.; Sun, B.; Wang, X.; Guo, H.; Zhang, L.; Chen, L.; Huang, H.; Li, W.; Pu, J. Integrated genomic analyses characterize molecular subtypes of meningioma and identify biomarkers of recurrence. Oncotarget 2017, 8, 40617–40631. [Google Scholar]
- Cao, S.; Zhang, X.; Xu, H.; Zhang, L.; Zhang, W.; Huang, B.; Chen, Y. Integrated analysis of microarray data to reveal biological pathways and key genes in meningiomas. J. Cell Mol. Med. 2020, 24, 2443–2454. [Google Scholar]
- Louis, D.N.; Perry, A.; Wesseling, P.; Brat, D.J.; Cree, I.A.; Figarella-Branger, D.; Hawkins, C.; Ng, H.K.; Pfister, S.M.; Reifenberger, G.; et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol. 2021, 23, 1231–1251. [Google Scholar] [CrossRef]
- Khangura, N.; Bhati, S.; Bhatia, G.; Goyal, N.; Khangura, S.K. A Histomorphological Study of Meningiomas According to Latest CNS 5th Edition WHO Classification 2021 and Co-relation of Grading with Ki-67 Proliferation Index. J. Med. Sci. Health 2024, 10, 241–246. [Google Scholar]
- Kleihues, P.; Cavenee, W.K. (Eds.) Pathology and Genetics of Tumours of the Nervous System; WHO Classification of Tumours, 3rd ed.; IARC Press: Lyon, France, 2000. [Google Scholar]
- Mancheño-Maciá, E. Potencialidad In Vitro de Muestras de Tejido Nervioso Sano y Tumoral de Pacientes Adultos. Ph.D. Thesis, Universidad Miguel Hernández de Elche, Elche, Spain, 2011. [Google Scholar]
- Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K. (Eds.) WHO Classification of Tumours of the Central Nervous System, Revised 4th ed.; IARC: Lyon, France, 2016. [Google Scholar]
- Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015, 43, e47. [Google Scholar] [CrossRef] [PubMed]
- Huang, D.W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44–57. [Google Scholar] [CrossRef]
- Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P.; et al. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019, 47, D607–D613. [Google Scholar] [CrossRef]
- Csárdi, G.; Nepusz, T. The igraph software package for complex network research. Complex Syst. 2006, 1695, 1–9. [Google Scholar]
- Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498–2504. [Google Scholar] [CrossRef]
- Biology Insights. Do Meningiomas Grow Back? Factors, Recurrence & Treatment. Biology Insights, 24 August 2025. Available online: https://biologyinsights.com/do-meningiomas-grow-back-factors-recurrence-treatment/ (accessed on 12 March 2026).
- Haddad, A.F.; Young, J.S.; Kanungo, I.; Sudhir, S.; Chen, J.-S.; Raleigh, D.R.; Magill, S.T.; McDermott, M.W.; Aghi, M.K. WHO Grade 1 meningioma recurrence: Identifying high-risk patients using histopathological features and the MIB-1 index. Front. Oncol. 2020, 10, 1522. [Google Scholar] [CrossRef]
- Sievers, P.; Hielscher, T.; Schrimpf, D.; Stichel, D.; Reuss, D.E.; Berghoff, A.S.; Neidert, M.C.; Wirsching, H.-G.; Mawrin, C.; Ketter, R.; et al. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol. 2020, 140, 409–413. [Google Scholar] [CrossRef]
- Beroukhim, R.; Mermel, C.H.; Porter, D.; Wei, G.; Raychaudhuri, S.; Donovan, J.; Barretina, J.; Boehm, J.S.; Dobson, J.; Urashima, M.; et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463, 899–905. [Google Scholar] [CrossRef]
- Zack, T.I.; Schumacher, S.E.; Carter, S.L.; Cherniack, A.D.; Saksena, G.; Tabak, B.; Lawrence, M.S.; Zhang, C.Z.; Wala, J.; Mermel, C.H.; et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 2013, 45, 1134–1140. [Google Scholar] [CrossRef]
- Groff, K.J.; Patel, R.V.; Feng, Y.; Ghosh, H.S.; Chavez, M.A.M.; O’BRien, J.; Chen, W.C.; Nitturi, V.; Save, A.V.; Youngblood, M.W.; et al. The effect of TERT promoter mutation on predicting meningioma outcomes: A multi-institutional cohort analysis. Lancet Oncol. 2025, 26, 1178–1190. [Google Scholar] [CrossRef]
- Gui, C.; Wang, J.Z.; Patil, V.; Landry, A.P.; Singh, O.; Castelo-Branco, P.; Tabori, U.; Aldape, K.; Behling, F.; Barnholtz-Sloan, J.S.; et al. Analysis of TERT association with clinical outcome in meningiomas: A multi-institutional cohort study. Lancet Oncol. 2025, 26, 1191–1203. [Google Scholar] [CrossRef]
- Landry, A.P.; Wang, J.Z.; Yefet, L.; Patil, V.; Liu, J.; Gui, C.; Ellenbogen, Y.; Ajisebutu, A.; Wei, Q.; Singh, O.; et al. Chromosome 1p loss and 1q gain are highly prognostic and can inform WHO grading of meningioma. Neuro Oncol. Adv. 2025, 7, iii5. [Google Scholar] [CrossRef]
- Traylor, J.I.; Plitt, A.R.; Hicks, W.H.; Mian, T.M.; Mickey, B.E.; Barnett, S.L. Evaluating risk of recurrence in patients with meningioma. J. Neurosurg. 2023, 138, 621–628. [Google Scholar] [CrossRef] [PubMed]
- Villa, A.; Rubio, F.J.; Navarro, B.; Bueno, C.; Martínez-Serrano, A. Human neural stem cells in vitro: A focus on their isolation and perpetuation. Biomed. Pharmacother. 2001, 55, 91–95. [Google Scholar] [CrossRef] [PubMed]
- Caldwell, M.A.; He, X.; Wilkie, N.; Pollack, S.; Marshall, G.; Wafford, K.A.; Svendsen, C.N. Growth factors regulate the survival and fate of cells derived from human neurospheres. Nat. Biotechnol. 2001, 19, 475–479. [Google Scholar] [CrossRef]
- Di Carlo, A.; Mariano, A.; Macchia, P.E.; Moroni, M.C.; Beguinot, L.; Macchia, V. Epidermal growth factor receptor in human brain tumors. J. Endocrinol. Investig. 1992, 15, 31–37. [Google Scholar] [CrossRef]
- Ishiwata, I.; Ishiwata, C.; Ishiwata, E.; Sato, Y.; Kiguchi, K.; Tachibana, T.; Ishikawa, H. In vitro culture of various typed meningiomas and characterization of a human malignant meningioma cell line (HKBMM). Hum. Cell 2004, 17, 211–217. [Google Scholar] [CrossRef]
- Yamate, J.; Tajima, M.; Saitoh, T.; Shibuya, K. Biological behaviour and morphological characteristics of a transplantable tumour (MM-KMY) derived from a malignant meningioma in an F344 rat. J. Comp. Pathol. 1994, 111, 243–257. [Google Scholar] [CrossRef]
- Tsujino, K.; Yamate, J.; Tsukamoto, Y.; Kumagai, D.; Kannan, Y.; Jippo, T.; Kuwamura, M.; Kotani, T.; Takeya, M.; Sakuma, S. Establishment and characterization of cell lines derived from a transplantable rat malignant meningioma: Morphological heterogeneity and production of nerve growth factor. Acta Neuropathol. 1997, 93, 461–470. [Google Scholar] [CrossRef]
- Gil-Salú, J.L.; García, L.; Díaz-Pérez, J.A.; García-Morales, I.; Martínez-Lacasa, C.; Barcia, J.A. Características citomorfológicas e inmunohistoquímicas de cultivos primarios obtenidos a partir de tumores cerebrales. Rev. Esp. Neurosci. 2000, 28, 81–91. [Google Scholar]
- Akat, K.; Ueda, H.; Zervas, N.T. Concomitant expression of epithelial and mesenchymal markers in human arachnoid cells and meningiomas. J. Neurooncol. 2003, 61, 1–11. [Google Scholar]
- Evans, S.M.; Gerson, S.L.; Hou, J. Cytokeratin and vimentin expression in human arachnoid cells and meningiomas. J. Pathol. 1998, 184, 153–158. [Google Scholar]
- Lee, W.H. Expression of intermediate filament proteins in human meningiomas. Acta Neuropathol. 1990, 80, 17–23. [Google Scholar] [CrossRef]
- Tanaka, K.; Sato, C.; Maeda, Y.; Koike, M.; Matsutani, M.; Yamada, K.; Miyaki, M. Establishment of a human malignant meningioma cell line with amplified c-myc oncogene. Cancer 1989, 64, 2243–2249. [Google Scholar] [CrossRef]
- Tsuchida, T.; Matsumoto, M.; Shirayama, Y.; Kasai, H.; Kawamoto, K. Immunohistochemical observation of foci of muscle actin-positive tumor cells in meningiomas. Arch. Pathol. Lab. Med. 1996, 120, 267–269. [Google Scholar] [PubMed]
- Hamilton, B.E.; Woltjer, R.L.; Prola-Netto, J.; Nesbit, G.M.; Gahramanov, S.; Pham, T.; Wagner, J.; Neuwelt, E.A. Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: A pilot study with immunohistochemical observations. J. Neurooncol. 2016, 129, 301–309. [Google Scholar] [CrossRef]
- Tamiolakis, D.; Papadopoulos, N.; Cheva, A.; Lambropoulou, M.; Kotini, A.; Jivannakis, T.; Simopoulos, C. Immunohistochemical expression of alpha-smooth muscle actin in infiltrating ductal carcinoma of the breast with productive fibrosis. Eur. J. Gynaecol. Oncol. 2002, 23, 469–471. [Google Scholar]
- Abd El-Rehim, D.M.; Pinder, S.E.; Paish, C.E.; Bell, J.; Blamey, R.W.; Robertson, J.F.; Nicholson, R.I.; Ellis, I.O. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 2004, 203, 661–671. [Google Scholar] [CrossRef]
- Barbieri, F.; Bajetto, A.; Dellacasagrande, I.; Solari, A.; Würth, R.; Fernandez, V.; Rancati, S.; Ceresa, D.; Appolloni, I.; De Luca, G.; et al. Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity. Neuro Oncol. 2023, 25, 1775–1787. [Google Scholar] [CrossRef]
- Chanas-Sacre, G.; Rogister, B.; Moonen, G.; Leprince, P. Radial glia phenotype: Origin, function, and transformation. Dev. Neurosci. 2000, 22, 477–488. [Google Scholar] [CrossRef]
- Dermietzel, R.; Hertzberg, E.L.; Kessler, J.A.; Spray, D.C. Gap junctions between cultured astrocytes: Immunocytochemical, molecular, and electrophysiological analysis. J. Neurosci. 1991, 11, 1421–1432. [Google Scholar] [CrossRef] [PubMed]
- Rook, M.B.; Jongsma, H.J.; van Ginneken, A.C. Properties of single gap junction channels between cultured heart cells of neonatal rats. J. Membr. Biol. 1992, 127, 189–197. [Google Scholar] [CrossRef]
- Sedovy, M.W.; Leng, X.; Leaf, M.R.; Iqbal, F.; Payne, L.B.; Chappell, J.C.; Johnstone, S.R. Connexin 43 across the vasculature: Gap junctions and beyond. J. Vasc. Res. 2023, 60, 101–113. [Google Scholar] [CrossRef] [PubMed]
- Sánchez, C.; de Ceballos, M.L.; del Pulgar, T.G.; Rueda, D.; Corbacho, C.; Velasco, G.; Galve-Roperh, I.; Huffman, J.W.; Ramón y Cajal, S.; Guzmán, M. Expression of cannabinoid receptors in central nervous system tumors. Cancer Res. 2001, 61, 5784–5789. [Google Scholar]
- De Jesús, M.L.; Hostalot, C.; Garibi, J.M.; Sallés, J.; Meana, J.J.; Callado, L.F. Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. Neurochem. Int. 2010, 56, 829–833. [Google Scholar] [CrossRef]
- Aguado, T.; Romero, E.; Monory, K.; Palazuelos, J.; Sendtner, M.; Marsicano, G.; Galve-Roperh, I. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J. Biol. Chem. 2007, 33, 23892–23898.
- McAllister, S.D.; Soroceanu, L.; Desprez, P.Y. The antitumor activity of plant-derived non-psychoactive cannabinoids. J. Neuroimmune Pharmacol. 2015, 10, 255–267. [Google Scholar] [CrossRef]
- Alexander, A.; Smith, P.F.; Rosengren, R.J. Cannabinoids in the treatment of cancer. Cancer Lett. 2009, 285, 6–12. [Google Scholar] [CrossRef]
- Milian, L.; Mata, M.; Alcacer, J.; Oliver, M.; Sancho-Tello, M.; Martín de Llano, J.J.; Camps, C.; Galbis, J.; Carretero, J.; Carda, C. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PLoS ONE 2020, 15, e0228909. [Google Scholar] [CrossRef] [PubMed]
- Khan, M.I.; Sobocińska, A.A.; Brodaczewska, K.K.; Zielniok, K.; Gajewska, M.; Kieda, C.; Czarnecka, A.M.; Szczylik, C. Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. BMC Cancer 2018, 18, 583. [Google Scholar] [CrossRef]
- Luca, T.; Di Benedetto, G.; Scuderi, M.R.; Palumbo, M.; Clementi, S.; Bernardini, R.; Cantarella, G. The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi’s sarcoma cells in vitro. Eur. J. Pharmacol. 2009, 616, 16–21. [Google Scholar] [CrossRef] [PubMed]
- MacLean, P.N.; Aldape, K.D. Molecular classification and grading of meningioma. J. Neuro Oncol. 2023, 161, 373–381. [Google Scholar]
- Clynch, A.; E Richardson, G.; A Mustafa, M.; Gillespie, C.S.; Rathi, N.; Bakhsh, A.; Zakaria, R.; I Islim, A.; Millward, C.P.; Jenkinson, M.D.; et al. Beyond the WHO classification of meningioma: Using molecular diagnostics to guide management. Adv. Clin. Neurosci. Rehabil. 2023, 22, 12–16. [Google Scholar] [CrossRef]
- Sahm, F.; Aldape, K.D.; Brastianos, P.K.; Brat, D.J.; Dahiya, S.; von Deimling, A.; Giannini, C.; Gilbert, M.R.; Louis, D.N.; Raleigh, D.R.; et al. cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro Oncol. 2025, 27, 319–330. [Google Scholar] [CrossRef]
- Kannapadi, N.V.; Shah, P.P.; Mathios, D.; Jackson, C.M. Synthesizing molecular and immune characteristics to move beyond WHO grade 1n meningiomas: A focused review. Front. Oncol. 2022, 12, 892004. [Google Scholar] [CrossRef] [PubMed]
- Lotsch, C.; Warta, R.; Herold-Mende, C. The molecular and immunological landscape of meningiomas. Int. J. Mol. Sci. 2024, 25, 9631. [Google Scholar] [CrossRef]
- Pereira, B.J.A.; Lerario, A.M.; Sola, P.R.; Laurentino, T.S.; Mohan, D.R.; de Almeida, A.N.; Pires de Aguiar, P.H.; da Silva Paiva, W.; Wakamatsu, A.; Teixeira, M.J.; et al. Impact of a cell cycle and an extracellular matrix remodeling transcriptional signature on tumor progression and correlation with EZH2 expression in meningioma. J. Neurosurg. 2022, 138, 649–662. [Google Scholar] [CrossRef]
- Goldbrunner, R.; Stavrinou, P.; Jenkinson, M.D.; Sahm, F.; Mawrin, C.; Weber, D.C.; Preusser, M. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021, 23, 1821–1834. [Google Scholar] [CrossRef] [PubMed]
- Xie, H.; Yuan, C.; Ding, X.; Li, J.; Li, Z.; Lu, W. Identification of key genes and pathways associated with resting mast cells in meningioma. BMC Cancer 2021, 21, 1209. [Google Scholar] [CrossRef]
- Hsu, S.M.; Raine, L.; Fanger, H. The use of avidin–biotin–peroxidase complex (ABC) in diagnostic parasitology. Am. J. Clin. Pathol. 1991, 95, 451–458. [Google Scholar]
- Li, Z.; Hecht, S.S. Metabolic activation and DNA adduct formation from N-nitrosamines. Chem. Res. Toxicol. 2022, 35, 197–220. [Google Scholar]
- Fahrer, J.; Christmann, M. DNA damage responses in cancer: Electrophiles, oxidative stress and adduct repair. Cancers 2023, 15, 1233. [Google Scholar]
- Hu, Y.; Cheng, R.; Tang, Y.; Zhang, R.; Shi, J.; Xu, C. Asporin contributes to tumor progression through the regulation of extracellular matrix organization and collagen interaction. Front. Oncol. 2021, 11, 665100. [Google Scholar]
- Vestweber, D. How leukocytes cross the vascular endothelium. Nat. Rev. Immunol. 2015, 15, 692–704. [Google Scholar] [CrossRef]
- Pruenster, M.; Rot, A. The atypical chemokine receptor D6 (ACKR2) and the regulation of immune responses. Trends Immunol. 2013, 34, 560–567. [Google Scholar] [CrossRef]
- Kunishio, K.; Yamamoto, T.; Sunaga, S.; Miyatake, S. Expression of multidrug resistance gene (MDR1) in meningiomas. J. Neuro Oncol. 2003, 62, 263–270. [Google Scholar]
- Schinkel, A.H.; Jonker, J.W. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2012, 81, 65–93. [Google Scholar]








| ProbeID | Gene Symbol | Gene Name | log2FC | Direction |
|---|---|---|---|---|
| 201131_s_at | ABCB1 | ATP-binding cassette sub-family B member 1 | 3.115135 | ↑ |
| 209994_s_at | ABCB1 | ATP-binding cassette sub-family B member 1 | 3.946437 | ↑ |
| 201596_x_at | KRT18 | Keratin 18 | 3.145330 | ↑ |
| 219529_at | CLIC3 | Chloride intracellular channel 3 | 3.886168 | ↑ |
| 216050_at | CYP2A6 | Cytochrome P450 family 2 subfamily A member 6 | 3.574162 | ↑ |
| 209994_s_at | CYP2B6 | Cytochrome P450 family 2 subfamily B member 6 | 4.209101 | ↑ |
| 201123_s_at | EIF5A | Eukaryotic translation initiation factor 5A | 3.191908 | ↑ |
| 204875_s_at | GMDS | GDP-mannose 4,6-dehydratase | 3.065947 | ↑ |
| 204987_at | ITIH2 | Inter-alpha-trypsin inhibitor heavy chain 2 | 3.116748 | ↑ |
| 221583_at | KCNMA1 | Potassium calcium-activated channel subfamily M alpha 1 | 3.593002 | ↑ |
| 201131_s_at | CDH1 | Cadherin 1 | 3.115135 | ↑ |
| 215894_at | PTGDR | Prostaglandin D2 receptor | 3.793593 | ↑ |
| 209904_at | TNNC1 | Troponin C1, slow skeletal and cardiac type | 4.498355 | ↑ |
| 202237_at | NNMT | Nicotinamide N-methyltransferase | −4.718362 | ↓ |
| 202238_s_at | NNMT | Nicotinamide N-methyltransferase | −4.040629 | ↓ |
| 209335_at | DCN | Decorin | −4.344368 | ↓ |
| 201893_x_at | DCN | Decorin | −3.832883 | ↓ |
| 211813_x_at | DCN | Decorin | −3.835581 | ↓ |
| 208335_s_at | ACKR1 | Atypical chemokine receptor 1 (Duffy blood group) | −3.031395 | ↓ |
| 221031_s_at | APOLD1 | Apolipoprotein L domain containing 1 | −3.898835 | ↓ |
| 222162_s_at | ADAMTS1 | ADAM metallopeptidase with thrombospondin type 1 motif 1 | −4.334914 | ↓ |
| 217546_at | ADAMTS1 | ADAM metallopeptidase with thrombospondin type 1 motif 1 | −4.334914 | ↓ |
| 2000897_s_at | PALLD | Palladin, cytoskeletal associated protein | −4.227503 | ↓ |
| 200907_s_at | PALLD | Palladin, cytoskeletal associated protein | −3.904815 | ↓ |
| 202672_s_at | ATF3 | Activating transcription factor 3 | −3.336215 | ↓ |
| 221541_at | CRISPLD2 | Cysteine-rich secretory protein LCCL domain containing 2 | −3.089719 | ↓ |
| 217546_at | MT1M | Metallothionein 1M | −3.647168 | ↓ |
| 201645_at | TNC | Tenascin C | −3.478160 | ↓ |
| 205207_at | IL6 | Interleukin 6 | −3.655819 | ↓ |
| 209774_x_at | CXCL2 | C-X-C motif chemokine ligand 2 | −4.770032 | ↓ |
| 204288s_at | SORBS2 | Sorbin and SH3 domain containing 2 | −3.122188 | ↓ |
| 36711_at | MAFF | MAF bZIP transcription factor F | −4.765884 | ↓ |
| 207961_x_at | MYH11 | Myosin heavy chain 11 | −3.146901 | ↓ |
| 201496_x_at | MYH11 | Myosin heavy chain 11 | −4.208234 | ↓ |
| 201497_x_at | MYH11 | Myosin heavy chain 11 | −4.147030 | ↓ |
| 203296_s_at | ATP1A2 | ATPase Na+/K+ transporting subunit alpha 2 | −3.426334 | ↓ |
| 216834_at | RGS1 | Regulator of G protein signalling 1 | −3.224255 | ↓ |
| 214677_x_at | KDM2A | Lysine demethylase 2A | −3.169647 | ↓ |
| 211430_s_at | PDCD1 | Programmed cell death 1 | −3.879132 | ↓ |
| 217022_s_at | HBB | Haemoglobin subunit beta | −3.481622 | ↓ |
| 209116_x_at | HBB | Haemoglobin subunit beta | −3.118670 | ↓ |
| 203485_at | RTN1 | Reticulon 1 | −3.904815 | ↓ |
| 212865_s_at | COL14A1 | Collagen type XIV alpha 1 chain | −3.347500 | ↓ |
| 209470_s_at | GPM6A | Glycoprotein M6A | −3.270120 | ↓ |
| 209469_at | GPM6A | Glycoprotein M6A | −4.030587 | ↓ |
| 209686_at | S100B | S100 calcium-binding protein B | −3.012154 | ↓ |
| 202508_s_at | SNAP25 | Synaptosome associated protein 25 | −3.511881 | ↓ |
| 201109_s_at | THBS1 | Thrombospondin 1 | −3.238524 | ↓ |
| 201110_s_at | THBS1 | Thrombospondin 1 | −3.515628 | ↓ |
| 204748_at | PTGS2 | Prostaglandin-endoperoxide synthase 2 | −3.297718 | ↓ |
| 206211_at | SELE | Selectin E | −3.334817 | ↓ |
| 210198_s_at | PLP1 | Proteolipid protein 1 | −4.037846 | ↓ |
| 219087_at | ASPN | Asporin | −3.669058 | ↓ |
| 209335_at | MBP | Myelin basic protein | −5.808051 | ↓ |
| 204939_s_at | PLN | Phospholamban | −4.402870 | ↓ |
| 202917_s_at | S100A8 | S100 calcium-binding protein A8 | −3.948918 | ↓ |
| 203540_at | GFAP | Glial fibrillary acidic protein | −3.290292 | ↓ |
| 221651_x_at | CYP2C19 | Cytochrome P450 family 2 subfamily C member 19 | −3.067765 | ↓ |
| 221671_x_at | CYP2C9 | Cytochrome P450 family 2 subfamily C member 9 | −3.070996 | ↓ |
| 216598_s_at | CCL2 | C-C motif chemokine ligand 2 | −3.269667 | ↓ |
| 200974_at | ACTA2 | Actin alpha 2, smooth muscle | −3.409686 | ↓ |
| Study | Key GO Terms | Key KEGG Pathways | Hub Genes (PPI) |
|---|---|---|---|
| Dai et al., 2017 [20] WHO grades 1, 2 + 3 vs. Meninges | Extracellular matrix organization Cell adhesion Angiogenesis Signal transduction | AGE-RAGE signalling pathway in diabetic complications PI3K-Akt signalling pathway TNF signalling pathway ECM-receptor interaction; Focal adhesion IL-17 signalling pathway MAPK signalling pathway NF-κB signalling pathway | JUN PIK3R1 FOS AGT MYC |
| Cao et al., 2020 [21] WHO grade 1 (all types) vs. Meninges | Extracellular matrix organization Inflammatory response Cell adhesion Extracellular space Integrin binding | Malaria Focal adhesion | AGT CXCL8 CXCL2 CXCL12 CXCR4 |
| Current Study DT-G1 vs. Meninges | Inflammatory response “Arachidonate epoxygenase activity” “Epoxygenase P450 pathway” “Xenobiotic catabolic process” Collagen-containing extracellular matrix Extracellular region Extracellular space Heme binding Monooxygenase activity “Oxidoreductase activity” Extracellular matrix organization (low significance) Cell adhesion (low significance) | “Lipid and aterosclerosis” Malaria IL-17 signalling pathway TNF signalling pathway “Cytoskeleton in muscle cells” “Arachidonic acid metabolism” “Chemical carcinogenesis—DNA adducts” “Drug metabolism—cytochrome P450” “African tripanosomiasis” “Retinol metabolism” | ASPN SELE ACKR1 ABCB1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Mancheño-Maciá, E.; Leal-Clavel, M.; Escudero-Ortiz, V. Establishment of the H8T-MG Meningioma Cell Line and Integrated Transcriptomics Reveal a Metabolic–Immune Signature in Diploid Transitional WHO Grade 1 Tumours. Biomolecules 2026, 16, 744. https://doi.org/10.3390/biom16050744
Mancheño-Maciá E, Leal-Clavel M, Escudero-Ortiz V. Establishment of the H8T-MG Meningioma Cell Line and Integrated Transcriptomics Reveal a Metabolic–Immune Signature in Diploid Transitional WHO Grade 1 Tumours. Biomolecules. 2026; 16(5):744. https://doi.org/10.3390/biom16050744
Chicago/Turabian StyleMancheño-Maciá, Esther, Marina Leal-Clavel, and Vanesa Escudero-Ortiz. 2026. "Establishment of the H8T-MG Meningioma Cell Line and Integrated Transcriptomics Reveal a Metabolic–Immune Signature in Diploid Transitional WHO Grade 1 Tumours" Biomolecules 16, no. 5: 744. https://doi.org/10.3390/biom16050744
APA StyleMancheño-Maciá, E., Leal-Clavel, M., & Escudero-Ortiz, V. (2026). Establishment of the H8T-MG Meningioma Cell Line and Integrated Transcriptomics Reveal a Metabolic–Immune Signature in Diploid Transitional WHO Grade 1 Tumours. Biomolecules, 16(5), 744. https://doi.org/10.3390/biom16050744

